Research
Start with the explainers — the category-level questions worth answering before you read anything else. Below them, a dated regulatory feed tracks approvals, warning letters and shortage movements; a structured study index gives every study a permalink; and an evidence digest for every compound waits at the bottom, one search away, stating what the literature supports and — as a required section — what it does not.
2 explainers · 11 regulatory entries · 102 studies indexed, 97 human · 28 compound digests
A certificate establishes what one laboratory measured in one lot on one date — and only if the document is checkable. The seven things to look for, the red flags that should stop you, and a worked example from a record in this index.
Read the guide· 8 minWhat does “studies show” actually mean here?Most peptide marketing rests on rodent and cell-culture work described in language that implies a human effect. What each tier of evidence can and cannot establish, why most preclinical findings do not replicate in people, and how to read a claim that cites a study.
Read the guide· 7 minDated entries tracking approvals, compounding-list movements, warning letters, shortage status and prohibited-list revisions — including recent FDA action against vendors selling GLP-1 and research peptides direct to the public.
Placeholder seed entry recording the source, not an event. The European Medicines Agency publishes decisions on marketing authorisation. Approval status matters to this index because it determines whether the substance in a research-grade vial has an approved counterpart at all — and therefore whether a published trial literature exists for a product that is not the one being sold.
Placeholder seed entry recording the source, not an event. The FDA maintains categorised lists of bulk drug substances nominated for use in compounding, including substances it has evaluated and placed in the category that may not be compounded. Several peptides tracked in this index have appeared in these evaluations. PepIndex records movements between categories here as they are observed; the linked page is the authoritative listing.
Placeholder seed entry recording the source, not an event. Shortage status for approved GLP-1 products materially affects this market: when an approved product is listed as in shortage, compounding of that substance becomes permissible under conditions, and demand shifts toward alternative supply. Resolution of a shortage reverses that. PepIndex records status changes here because they move the whole category.
Placeholder seed entry recording the source, not an event. The FDA publishes warning letters issued to firms, including sellers marketing unapproved products or making disease claims. Where a letter names a vendor tracked in this index, PepIndex records it here and links it from that vendor's profile. No vendor currently in the index has such a letter recorded against it.
Placeholder seed entry recording the source, not an event. The UK regulator has published guidance and enforcement positions on the supply of unlicensed medicines to the public, including substances marketed as research chemicals. Several compounds tracked here have been the subject of public statements. PepIndex records those affecting indexed compounds.
Placeholder seed entry recording the source, not an event. The World Anti-Doping Agency publishes an annual Prohibited List; class S2 covers peptide hormones, growth factors, related substances and mimetics. Several compounds tracked in this index fall within that class or its catch-all clause. The list is revised annually and takes effect on 1 January. PepIndex records revisions affecting indexed compounds here.
Every study is stored once and referenced wherever it is relevant. Each has a permalink, an evidence type, the model it used and what it reported.
Across every compound tracked, most of the indexed literature is preclinical — the single most useful thing to know before reading any digest below.
Pick a compound above to read what the published literature does — and, just as importantly, does not — establish for it.